Sugi Predict

Sugi Predict / Compounds / SCHEMBL488417

SCHEMBL488417

SCHEMBL488417

Nc1ncc(-c2cccc(NS(=O)(=O)CCN3CC[C@@H](O)C3)c2)nc1OCc1c(F)ccc(F)c1Cl

nearest known ligand 0.39

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ TYRO3 Q06418 6/20 0.39
▸ CSF1R P07333 2/20 0.38
▸ ATR Q13535 1/20 0.38
▸ PDCD1 Q15116 4/20 0.36
▸ CD274 Q9NZQ7 4/20 0.36
▸ MET P08581 2/20 0.36
▸ PIK3CD O00329 2/20 0.36
▸ PIK3CA P42336 2/20 0.36
▸ PIK3CB P42338 2/20 0.36
▸ PIK3CG P48736 2/20 0.36
▸ PLA2G4A P47712 1/20 0.35
▸ MAP4K4 O95819 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30453003 1.00 TYRO3 (0.39) TYRO3CSF1RATRPDCD1CD274
SCHEMBL30452628 0.96 TYRO3 (0.40) TYRO3CSF1RATRMETPIK3CD
SCHEMBL488554 0.96 TYRO3 (0.40) TYRO3CSF1RATRMETPIK3CD
SCHEMBL30452859 0.92 TYRO3 (0.39) TYRO3CSF1RATRPDCD1CD274
SCHEMBL488117 0.92 TYRO3 (0.39) TYRO3CSF1RATRPDCD1CD274
SCHEMBL10216235 0.92 TYRO3 (0.39) TYRO3CSF1RATRPDCD1CD274
SCHEMBL488165 0.92 CSF1R (0.40) CSF1RATRPDCD1CD274MET
SCHEMBL30452621 0.92 CSF1R (0.40) CSF1RATRPDCD1CD274MET
SCHEMBL488776 0.90 CSF1R (0.39) TYRO3CSF1RATRPDCD1CD274
SCHEMBL487930 0.89 MAP4K4 (0.45) TYRO3CSF1RATRMETPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106197-B2 Aminoheteroaryl compounds as protein kinase inhibitors PFIZER INC. (US) 2012-01-31 — — US disclosed
US-8106197-B2 Aminoheteroaryl compounds as protein kinase inhibitors PFIZER INC. (US) 2012-01-31 — — US disclosed
US-8106197-B2 Aminoheteroaryl compounds as protein kinase inhibitors PFIZER INC. (US) 2012-01-31 — — US disclosed
US-7230098-B2 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer SUGEN, INC. (US) 2007-06-12 — — US disclosed
US-7230098-B2 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer SUGEN, INC. (US) 2007-06-12 — — US disclosed
US-20070072874-A1 Aminoheteroaryl compounds as protein kinase inhibitors SUGEN, INC. 2007-03-29 — — US disclosed
US-20070072874-A1 Aminoheteroaryl compounds as protein kinase inhibitors SUGEN, INC. 2007-03-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072874-A1 Aminoheteroaryl compounds as protein kinase inhibitors MET, MAP4K1, MAP4K2 TYRO3 416/4885CSF1R 757/4885ATR 1416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.